Cebranopadol Production Cost Reports

The report provides a detailed analysis essential for establishing a Cebranopadol production plant. It encompasses all critical aspects necessary for Cebranopadol production, including the cost of Cebranopadol production, Cebranopadol plant cost, Cebranopadol production costs, and the overall Cebranopadol production plant cost. Additionally, the study covers specific expenditures associated with setting up and operating a Cebranopadol production plant. These encompass production processes, raw material requirements, utility requirements, infrastructure needs, machinery and technology requirements, manpower requirements, packaging requirements, transportation requirements, and more.

Cebranopadol is an analgesic drug that works as a dual agonist at opioid and nociceptin receptors. It provides better pain relief while reducing risks like respiratory depression, tolerance, dependence, and abuse potential. It targets chronic moderate-to-severe pain conditions, including neuropathic pain from diabetic neuropathy and post-herpetic neuralgia.

It is also utilised in cancer pain, osteoarthritis, low back pain, and acute nociceptive pain, where it works better than traditional methods. It has oral efficacy and safety for non-opioid-dependent patients, making it a preferred alternative for long-term pain management. Its common side effects include nausea, dizziness, vomiting, drowsiness, constipation, headache, fatigue, and sweating, mostly mild and less frequent than traditional opioids.

The market for Cebranopadol is influenced by the increasing global burden of chronic pain conditions. Its utilisation in neuropathic pain, low back pain, osteoarthritis, and cancer pain, amid the opioid crisis demanding non-addictive alternatives, contributes to its market growth. Its lower abuse liability and side effects in comparison to other opioids fuel its demand.  Also, positive Phase 3 trial results (e.g., ALLEVIATE-1 showing superior analgesia post-surgery) and FDA Fast Track Designation for chronic low back pain fuel its market.

The industrial Cebranopadol procurement is affected by API sourcing risks from complex spiro-cyclic synthesis requiring specialised GMP manufacturers. Also, long clinical and regulatory timelines, high R&D costs, and potential supply chain vulnerabilities like single-sourcing or raw material shortages affect its sourcing strategies.

Raw Material for Cebranopadol Production

According to the Cebranopadol production plant project report, the key raw materials used in the production of Cebranopadol include Fluoro-Silyl-Indole Derivative and Cyclohexanone Azido-Dimethylamine Derivative.

Production Process of Cebranopadol

The extensive Cebranopadol production cost report consists of the following major industrial production process:

1. By Cyclisation Reaction: The production process of Cebranopadol involves several steps. First, a substituted indole intermediate is prepared using classical indole-forming chemistry from commercially available aniline derivatives. This indole is then coupled with a functionalised cyclohexanone or cyclohexyl precursor bearing a tertiary amine side chain. Subsequent acid-catalysed intramolecular cyclisation under controlled conditions generates the spiro[indole-cyclohexane] framework with high diastereoselectivity. Final deprotection and functional group adjustments give cebranopadol as the final product.

Cebranopadol is a synthetic spirocyclic compound that has the molecular formula of C24H27FN2O and a molecular weight of 378.49 g/mol. It appears as a white to off-white solid at room temperature. It shows low water solubility but dissolves well in organic solvents like DMF and DMSO. It has a boiling point of around 547 degree Celsius with a flash point near 285 degree Celsius. It has a lipophilic profile with an XLogP3 value of 4.3-4.74. It has a pKa (strongest basic) around 9.92, a physiological charge of +1, a hydrogen bond donor count of 1, an acceptor count of 2, a polar surface area of 28.26 Ų, and rotatable bonds of 2, making it orally bioavailable. It requires storage at -20 degree Celsius under inert conditions to prevent degradation.